Ashland Inc. (ASH) Earnings Call Transcript & Summary
November 4, 2026
Earnings Call Speaker Segments
Sandy Klugman
executiveThanks, operator. Morning, everyone, and thanks for joining us for Ashland's conference call and webcast covering fourth quarter and full-year fiscal 2026 results. I'm Sandy Klugman, Director of Investor Relations at Ashland. With me today are Guillermo Novo, our Chair and CEO; William Whitaker, our CFO; and the leaders of our business units: Alessandra Faccin, who heads Life Sciences and Intermediates; Jim Minnicucci, Personal Care; and Dago Caceres, Specialty Additives. Just a note that slides will be referenced during today's call. We'd encourage you to follow along with the webcast materials, which you can find at ashland.com under Investor Relations. Please turn to slide 2. Just a quick note before we begin: this presentation includes forward-looking statements regarding our fiscal 2027 outlook and other topics, which are laid out on slide 2 and in our Form 10-K. Those statements carry risks and uncertainties that might make actual future results differ materially from what we project today. We feel the statements rest on reasonable assumptions, though we can't guarantee that these expectations will be met. We'll also be citing some adjusted financial metrics, both actual and projected, and these are non-GAAP measures. We show these adjusted figures so you get extra insight into how our business is performing on an ongoing basis. You can find reconciliations on our website and in the presentation's appendix. At this point, I'll pass things along to Guillermo so he can give his opening comments.
Guillermo Novo
executiveThanks, Sandy, and hello to everyone who's with us. I'll begin by summarizing how we did in the fourth quarter and across all of fiscal 2026. After that, William will walk through the financials, our cash generation, and what we expect for fiscal 2027. Next, our business leaders will share more detail on how each segment performed, and I'll come back at the close to talk about our innovation platforms and the priorities we've set for the coming year. If you'd turn to slide 5. We finished fiscal 2026 with sustained robust commercial results in our core segments: pharma, personal care, and coatings and performance specialties within Specialty Additives. Intermediates posted a healthy gain in profitability. Life Science sales were up 4%, driven by widespread pharma growth across the major regions and technology platforms. Pharma posted year-over-year volume growth for a sixth straight quarter, helped along by ongoing momentum from our Globalize and Innovate strategies. Sales in Personal Care rose 8%, driven by double-digit gains in biofunctional actives, microbial protection, and hair care, plus high single-digit growth in skin care. Within Specialty Additives, coatings grew 9% and performance specialties grew 14%. China notched its third quarter in a row of year-over-year sales growth. Intermediates held steady, and profitability came in stronger, as a favorable merchant mix, pricing, and cost performance drove margin expansion. Even with volatility in raw materials and freight, our teams executed well, and disciplined pricing action offset cost inflation across every one of our business units. Hopewell has its key process upgrades and essential investments completed, and the team is now focused on execution—raising output and productivity while lifting profitability in Specialty Additives. Another strong point was cash generation, since reduced working capital helped drive operating cash flow higher and supported steady free cash flow conversion. Turning to slide 6, sales on the top line rose 4%, volumes climbed 3%, led by Life Science, Personal Care, coatings, and performance specialties, and pricing gained 2%, offsetting cost inflation in every business unit. All in all, the fourth quarter delivered strong underlying earnings, with adjusted EBITDA up double digits in Life Science, Personal Care, and Intermediates, partly offset by the operating results in Specialty Additives. Overall, the quarter showed solid fundamental results across a large portion of our portfolio, and it also made clear we have a real chance to turn sustained commercial momentum into better consolidated profitability by improving how we operate. If you would go to slide 7. Across the portfolio, two points stand out this quarter. First, our faster-growing Life Science and Personal Care segments kept up their good performance. Life Science posted a record adjusted EBITDA margin of about 36%, and Personal Care posted a margin above 30%. Both segments produced robust revenue growth and significant margin expansion, helped by outperformance on our Execute, Globalize, and Innovate priorities. Second, our core Specialty Additives businesses, coatings and performance specialties, keep beating their markets. Those businesses delivered solid results, but their gains were counterbalanced by the Iran war's effect on our Energy and Resources unit and by steps we took to cut back our construction segment exposure. Specialty Additives' overall profitability felt the expected strain from Hopewell's productivity levels. Intermediates turned in a strong showing, expanding margins despite persistently challenging market conditions. With fiscal 2027 now underway, our focus is on driving growth in our core businesses, keeping margins stable, and improving how well our manufacturing operations perform. Before William takes over, I want to step back and put our full-year results in context. Please turn to slide 8. Fiscal 2026 showed the fundamental strength of our portfolio, with robust growth and profitability in Life Science and Personal Care, plus improving commercial momentum in coatings and performance specialties. That momentum gained traction as the year went on. Sales for the second half rose roughly 6% compared with the prior year. Our Globalize and Innovate strategies beat their growth targets, and our teams showed rigorous pricing discipline, recouping cost inflation throughout the portfolio. On the operational side, we bounced back from the Calvert City outage, which supported stronger operating and financial results across the portfolio. We likewise produced robust cash generation, which further bolstered our financial flexibility. As we head into fiscal 2027, we do so from a position of strength — commercial momentum is solid, pricing has been disciplined, and our financial footing is healthy. Our priorities are straightforward: continue expanding the higher-value parts of our business, keep advancing the innovation pipeline, and convert improved manufacturing performance into better earnings and cash flow. With that said, I'll turn things over to William, who will take you through the details of our fourth quarter financial performance. William?
William Whitaker
executiveThanks, Guillermo. Let's move to slide 10. Sales in the fourth quarter came in at $498 million, a 4% gain versus the same quarter last year. Volume was up 3%, with Life Sciences and Personal Care leading the way, plus continued growth in coatings and performance specialties. Price rose 2% and offset cost inflation throughout the business units. Currency effects trimmed sales by roughly $3 million. Adjusted EBITDA reached $121 million, 2% higher than the prior-year quarter. The main growth drivers were higher volume, favorable mix, and pricing, which supported double-digit adjusted EBITDA growth in Life Sciences, Personal Care, and Intermediates; those gains were partly offset by unfavorable absorption in Specialty Additives and higher unallocated corporate expense, mainly incentive compensation. Currency also cut adjusted EBITDA by about $2 million. Adjusted operating income rose to $77 million from $71 million. Adjusted income from continuing operations, excluding intangible amortization expense, came to $52 million, or $1.12 per diluted share, versus $50 million, or $1.08 per diluted share, a year earlier. Cash flow from operating activities was $90 million, up from $40 million in the prior-year quarter, driven mainly by lower working capital. Ongoing free cash flow was $74 million versus $52 million, a conversion of 61% of adjusted EBITDA compared with 44% in the prior-year quarter. As we head into fiscal 2027, we expect working capital to rise modestly from these year-end levels; we finish fiscal 2026 with $480 million in cash, $976 million of total liquidity, and net leverage of 2.3 times, which supports financial flexibility as we enter fiscal 2027; with that, I'll hand the call to our business unit leaders for a closer look at segment performance. Alessandra, over to you for Life Sciences.
Alessandra Faccin
executiveThank you, William, and good morning to everyone. If you'd please go to slide 11, that covers Life Sciences. We had yet another robust quarter in Life Sciences, with sales up 4% to $180 million. Pharma sales rose roughly 6%, which marks our sixth quarter in a row of year-over-year volume growth. Results were broad-based across the major regions and technology platforms, including VP&D, cellulosics, injectables, and film coatings. Nutrition sales came in slightly lower on reduced volumes, mainly because of the timing of new customer wins in Latin America, which we expect to contribute positively during 2027. Pricing was up about 1% versus the prior year and covered cost inflation. Foreign currency cut segment sales by roughly $1 million. Our Globalize and Innovate strategy continues to drive growth in pharma, with strong results in injectables and film coatings and rising uptake of newer, higher-value products. During the quarter we introduced Permaxa?, sodium caprate, a permeation enhancer for oral biologics, and over 60 active customer engagements are now in progress, which moves our strategy forward to create differentiated solutions for oral delivery of biologic therapies. Turning to profitability, adjusted EBITDA increased 16% to $64 million, and adjusted EBITDA margin widened 380 basis points to a record 35.6%, reflecting the ongoing shift toward high-value applications and solid execution throughout the business. That gain was driven mainly by higher volumes across the board, favorable product mix, pricing, and cost performance. As we enter fiscal 2027, Life Sciences is carrying solid commercial momentum, backed by ongoing pharma growth and meaningful chances to broaden our differentiated portfolio around the world and scale high-impact innovations launched recently. I'd ask you to turn to slide 12, where we cover Intermediates. Intermediates sales came in at $33 million, matching the prior-year quarter. Merchant sales climbed 4% even though volumes were slightly lower, which reflects a favorable mix, with NMP continuing to show strength and lower merchant BDO volumes partly offsetting that. Captive sales dropped by roughly $1 million, reflecting reduced downstream production requirements. Pricing kept pace with raw material cost inflation, and foreign currency's effect on sales was negligible. Turning to profitability, adjusted EBITDA rose to $6 million from $5 million, and adjusted EBITDA margin widened 300 basis points to 18.2%. That gain came from a better merchant mix, careful pricing, and solid cost control, though softer volumes partly offset it. Notably, we achieved a substantial margin gain even as conditions across the broader BDO market stayed difficult. Going forward, we anticipate recently signed customers beginning to ramp in fiscal 2027, which adds another catalyst for growth as we keep running the business with discipline. I'll now turn the call over to Jim for Personal Care.
Jim Minnicucci
executiveThanks, Alessandra. Now I'll walk you through how Personal Care performed. Slide 13 covers Personal Care. We posted another robust quarter in Personal Care, with sales up 8% to $163 million — that marks a third straight quarter of mid-single-digit growth. As in earlier quarters, the gains came mainly from volume growth that was broad-based across every region and most major markets. Our commercial engine kept building momentum, and strong execution sped up growth as the year went on. Both of our Globalize businesses — biofunctional actives and microbial protection — posted double-digit growth, which speaks to strong customer adoption and demand. In biofunctional actives, Colla-peptide? and Eternight? kept landing strong commercial wins. Microbial protection kept picking up share, helped by the investments we made to strengthen regional manufacturing capabilities and our cost position. Care ingredients sales rose roughly 7%, led by double-digit growth in hair care and high single-digit growth in skin care, while oral care and household together dipped slightly, mainly because of order timing. Pricing offset raw material cost inflation, and foreign currency cut sales by about $1 million. In the quarter we launched EZ-hance?, a super-wetting agent built specifically for curly hair that enables faster, more efficient wetting while improving detangling, fiber alignment, and product performance in both leave-on and rinse-off applications. On profitability, adjusted EBITDA rose 14% to $49 million, and adjusted EBITDA margin was up 160 basis points to 30.1%. Higher volumes and favorable mix, along with disciplined pricing and cost performance, kept margins above 30% even as we keep investing for growth. Personal Care heads into fiscal 2027 from a position of strength. Our commercial engine is gaining momentum, our Globalize businesses are growing, and our innovation pipeline keeps opening new opportunities with customers. Our focus is clear: sustain the momentum, gain share, and turn our innovation into durable, profitable growth. With that, I'll hand the call to Dago to review Specialty Additives.
Dago Caceres
executiveThanks, Jim. If you'd go to slide 14. Specialty Additives sales came in at $130 million, which matched the prior-year quarter. Sales in Coatings rose by a high single-digit percentage, and performance specialties posted double-digit growth, with share gains continuing across regions even though end-market conditions were challenging. China recorded its third quarter in a row of year-over-year sales growth. Those gains were offset by softer end-market demand in Energy and Resources, while lower construction volumes reflected deliberate portfolio choices aimed at prioritizing higher-value applications. The team also kept executing well on pricing. Pricing rose roughly 5% and covered raw material cost inflation, showing continued discipline in a volatile cost environment. Foreign currency cut segment sales by about $1 million. On profitability, adjusted EBITDA was $20 million versus $29 million in the prior-year quarter, and the adjusted EBITDA margin was 15.3%. The decline mainly reflected the expected lower productivity output at Hopewell. We've addressed key process gaps and finished the critical investments needed to support near-term performance. Our focus now is execution, and the team is working to raise output and productivity over the coming months. Importantly, the team keeps delivering strong commercial performance across coatings and performance specialties, with share gains across regions and disciplined pricing execution. With that, I'll hand the call back to William.
William Whitaker
executiveAppreciate that, Dago. Turning to slide 16, I'd like to provide a year-end recap on the Execute strategy and what we've been doing on manufacturing productivity. Over the course of fiscal 2026, we completed a number of meaningful structural components of Execute. Our VP&D optimization efforts, combined with the push to consolidate small plants, generated approximately $18 million in benefits — $15 million attributable to VP&D and $3 million from small-plant consolidation. VP&D exceeded our expectations, with strong execution across a number of areas that contributed to margin improvement. At Hopewell, we continue advancing our comprehensive plan aimed at boosting productivity and output. Initiatives across people, process, and assets are beginning to translate into stronger manufacturing performance. The plan is set, key investments are committed, and our attention now is on execution. Stronger commercial prospects across the portfolio will be supported by greater output and improved asset utilization, which in turn should lift profitability. In summary, the structural cost base has been reduced through our Execute initiatives, and the operating foundations are now stronger. With our footprint actions finished, we turn our attention to realizing the full economic benefits. Slide 17, please. Turning to Globalize and Innovate, fiscal 2026 served as a significant proof point for both strategies, as each produced results far exceeding the goals we had set at the start of the year. Taken together, Globalize and Innovate generated roughly $52 million in incremental sales, which is almost 50% higher than the $35 million we had targeted for fiscal 2026 on a combined basis. What matters is that this contribution was spread broadly across the portfolio, since our spending on new capabilities, technologies, and geographic expansion is increasingly converting into commercial growth. Globalize accounted for about $26 million in incremental sales, compared with our fiscal 2026 target of $20 million. That growth was driven by sustained momentum in biofunctional actives, microbial protection, injectables, and tablet coatings, which reflects the investments we have made to broaden our capabilities and reinforce our position in key regions. Innovate accounted for about $26 million in incremental sales, compared with our fiscal 2026 target of $15 million. Results showed growing commercialization plus customer uptake of distinctive technologies and newly introduced products throughout our main markets. Our teams made progress in fiscal 2026 that leaves us quite encouraged; those figures demonstrate that what we invested is now producing business results, and they hand us a wider set of opportunities to develop further. Looking ahead to fiscal 2027, our priority is to capitalize on that momentum—growing the opportunities where customer demand is strongest, broadening adoption among existing clients and across geographies, and moving additional opportunities forward through the commercial pipeline. For fiscal 2027, our targets are roughly $20 million in incremental Globalize sales and $45 million in incremental Innovate sales, which works out to a 25% rise in combined incremental sales compared with 2026. At this point I'd like to step back, as Guillermo mentioned earlier. Fiscal 2026 demonstrated that the transformative steps we've taken over recent years — reshaping the portfolio, streamlining our footprint, and investing in Globalize and Innovate — created a very solid base; we witnessed that in how we bounced back from the Calvert City outage earlier this year, with adjusted EBITDA margin rising roughly 400 basis points between the second and fourth quarters, and that included a record margin for Life Sciences plus 30%-plus margins for Personal Care. Globalize and Innovate exceeded their combined target by nearly 50%, VP&D optimization came in ahead of expectations, and our pricing moves are recouping cost inflation throughout the businesses. We additionally delivered free cash flow conversion that surpassed our 50% commitment and brought net leverage down into our long-term target range. Now that this foundation is in place, the key priority for fiscal 2027 is execution—converting those gains into sustainable earnings growth. Please turn to slide 18, where the fiscal 2027 outlook is presented. Our plan factors in sustained commercial momentum and improved operating performance, balanced against a cautious assessment of worldwide demand, raw material and freight volatility, and a firmer U.S. dollar. Sales for fiscal 2027 are expected to come in at $1.905 billion to $1.975 billion, and adjusted EBITDA should be in the $405 million to $435 million range. Regarding ongoing free cash flow, we expect conversion to exceed 40% of adjusted EBITDA. That projection includes a moderate buildup in inventory and capital spending reaching roughly $140 million. We expect demand to remain steady in Life Sciences and Personal Care, supported by continuing momentum in pharma and expansion in our higher-value Personal Care applications. Within Specialty Additives, we expect coatings and performance specialties to carry forward their recent commercial momentum, while construction and energy and resources continue to face weak end markets. First-quarter year-over-year comparisons begin to ease as we lap last year's declines; we have scheduled maintenance at our cellulosics assets in the first quarter of this year, which moves part of Specialty Additives' earnings weighting into the remainder of the year. Within Intermediates, business recently secured from customers creates additional chances to grow during fiscal 2027, although exactly when and how quickly those new volumes arrive depends on how fast clients ramp up production. Throughout the portfolio, Globalize and Innovate should build on the substantial gains achieved in fiscal 2026 and remain contributors to growth. We likewise expect raw material and freight expenses to stay volatile. As input costs shift, we will continue handling pricing in a disciplined way, and our guidance presumes that price adjustments will counter the inflation we foresee across the year. Looking ahead to fiscal 2027, Ashland aims to capture about $10 million in net productivity and manufacturing optimization gains. Those gains should come from continued advances in the HEC and VP&D networks, along with the small-plant consolidation initiative reaching full realization, though the carryover effect of reduced Hopewell output in fiscal 2026 will partly offset them. At Hopewell, we anticipate extending the recent progress we described earlier, as better output and asset utilization underpin progressively stronger Specialty Additives results through the year. We also expect first-half results to benefit from comparisons with last year's operational effects at Calvert City, which should support margins in Life Sciences, Personal Care, and Intermediates. Our outlook further reflects a firmer U.S. At recent spot rates, that translates to a dollar impact—roughly $20 million to $25 million in sales headwinds and about $7 million to $10 million in adjusted EBITDA. Having said that, I'll turn things back over to Guillermo, who'll walk through our innovation pipeline and the priorities we've set for fiscal 2027. Guillermo?
Guillermo Novo
executiveThank you, William. Let's move to slide 19. For Ashland, innovation continues to be a central force behind differentiation and growth over the long term. During the innovation webinar we held in September, we noted that our technology platforms have advanced considerably — moving from technical and commercial validation toward commercialization. Customer engagement is still robust, and we are working more and more closely with customers to turn these technologies into concrete products and applications. We have likewise strengthened the regulatory and manufacturing capabilities required to support commercialization and scaling of these technologies. Within our seven scalable technology platforms, we have filed more than 50 patents and introduced 23 products, 12 of which have launched since May 2025. Opportunities from these technologies span pharma, personal care, and coatings. Tangible commercialization progress is also visible across the portfolio. Multiple platforms have progressed past the validation stage into commercial launch and wider commercial adoption, which gives us several avenues for growth. Our attention now centers on commercialization, customer adoption, and disciplined scaling. We are putting priority on the opportunities with the strongest customer validation and the clearest routes to scale. Importantly, our approach to investment is a disciplined one. We can fund the early phases of commercialization largely using existing manufacturing capabilities and infrastructure, with further investments tied to customer adoption and demand. The portfolio's breadth, robust customer engagement, and ongoing progress toward commercialization deepen our confidence that innovation is a key long-term growth driver for Ashland. Let's move to slide 20. With fiscal 2027 beginning, our priorities are clear: we will build on the differentiated growth we see in pharma, personal care, coatings, and performance specialties, and keep expanding our higher-value business around the world; we will push forward across our manufacturing network, turning our optimization actions into greater reliability, productivity, and profitability, with continued improvement at Hopewell remaining a key priority; we will speed up commercialization and customer adoption across our innovation platforms, and keep scaling our Globalize initiatives; and we will stay focused on cash generation and disciplined capital allocation, underpinned by our strong balance sheet and financial flexibility. Fiscal 2026 showed that we can deliver, even against a challenging market backdrop. We built strong commercial momentum, made meaningful progress across our strategic initiatives, and generated strong cash. As fiscal 2027 begins, our focus is on carrying that momentum forward and converting the progress we have made into sustained growth, improved profitability, and strong cash flow. We have the right priorities, a strong portfolio, and clear opportunities within our control to keep improving performance. I want to thank our employees for their continued commitment, customer focus, and execution throughout fiscal 2026, and I also want to thank our shareholders for their continued support and engagement. Operator, please open the line for Q&A.
Chris Parkinson
analystHi, this is Reed filling in for Chris. Thanks for taking my question. I was wondering whether you could speak about the personal care market. It seems as though it's inflecting after a number of years of choppiness, and I'm just wondering how sustainable you believe that is and what you're hearing from your customers.
Guillermo Novo
executiveJim, would you like to handle that one? I’ll just say in general that it looks quite strong across every region and area. Of course, as Jim mentioned, much of the growth comes from things we control on the new innovations and Globalize, Innovate side. There are plenty of levers that are favorable to us going forward. Jim, do you want to go into more detail?
Jim Minnicucci
executiveThanks, Guillermo, and I appreciate the question. As we've mentioned on earlier calls and in previous quarters, growth has kept speeding up as we've progressed through the fiscal year. Looking specifically at the 8% growth in Q4, the key thing to stress is, first, that volume was the main driver. Price was favorable compared with the prior year, which covered cost inflation. As we've said before, ingredients make up only a small share of the customer's cost stack—we're truly the performance engine—but we did take the pricing steps needed to cover costs. Volume accounted for the bulk of growth, about 7%, and that's one of the main signals giving us confidence that the performance can be sustained, since it comes from volume. I'd also note that when you look at that 8% growth, it's genuinely broad-based across the portfolio: about half came from our Globalize segments, biofunctional actives and microbial protection, with each of those growing north of 10%; the other half came from our care ingredients portfolio, the polymer portion, which reflected a mix of the innovation launches we've had plus the base business. Very, very broad-based.
Chris Parkinson
analystUnderstood. All right, thanks. Then I have one more question about Life Sciences. Would you discuss the margin gain in that segment once more — how durable do you believe it is — and, more broadly, how enthusiastic are you regarding the pharma pipeline?
Guillermo Novo
executiveAlessandra, you want to take that?
Alessandra Faccin
executiveOkay. So really, on the margin side for Q4, it comes down to what we mentioned before — we had robust volume in pharma and a favorable mix. The approach of building growth momentum around innovation and Globalize is clearly paying off. We can see that in the top line as well as in the favorable mix. On pricing, it's quite close to what Jim laid out for Personal Care. We've put price increases in place to offset inflation, but honestly the top line and the bottom line both benefited from growth and volume momentum. And yes, there's real enthusiasm around the pipeline — in this business the pipeline matters a great deal and is closely linked to what our customers have in their own pipelines. The growth momentum you're seeing reflects exactly that. In Q4, specifically for pharma, we had overall growth of 6.1%, with 6.4 coming from volume. We're clearly seeing the payoff of our emphasis on share gains, Globalize, and Innovate, with wins across cellulosics, film coatings, and injectables. As we also mentioned, VP&D was positive in both the third and fourth quarter. We've observed stabilization in VP&D, which is really encouraging.
Chris Parkinson
analystThank you.
Sandy Klugman
executiveOperator, can we please move to the next question?
Laurence Alexander
analystHello, and good morning. Kevin here, filling in for Laurence. Thanks for taking my questions. I suppose my first one concerns free cash flow conversion. You're guiding to roughly that 40%-plus conversion in '27. I'm just wondering, I guess, what we ought to treat as a more normalized rate of free cash flow conversion past 2027.
Guillermo Novo
executiveI'll keep this at a high level, and William, feel free to fill in the specifics. On the CapEx front, we aren't making much of a change. The big item, I'd say, is what we've done with HEC through network optimization, and there are two pieces to it. First, we're focused on improving productivity at a single plant for one product line, which has been the problem area this year. Looking further out, we definitely want to ensure we're adding debottlenecking capacity for 2030. At the moment, macro demand in coatings has been somewhat muted. This year, for instance, we anticipated a pickup in North America, and it didn't materialize. For next year, we're likewise projecting a subdued environment. The thing is, there's substantial pent-up demand in housing and real estate. There are a lot of factors at play. At the same time, we could see demand pick up in '27 and '28. Instead of waiting until late '27 or '28 to add those debottlenecking projects, we've simply chosen to pull them forward, so we're ready for any upside that might emerge in the later years of our planning process. It really comes down to CapEx timing more than anything else. William, I don't know whether you'd like to add anything...
William Whitaker
executiveHey, Kevin. Morning. On free cash flow, looking ahead, we continue to anticipate it exceeding 50% of adjusted EBITDA. Clearly, this year was quite robust at 60%. For this year, our guidance is above 40%. Guillermo touched on part of this, but regarding CapEx, the guide shows a rise from $90 to $140. I want to emphasize that this is the "up to" figure. We chose to build in some flexibility around project timing, and we'll keep you updated as the year goes on regarding when those key projects land. Really, when it comes to capital allocation priorities, that piece stays the same: maintenance CapEx, disciplined, and on that front. We've kept realizing and benefiting from the savings tied to some asset footprint rationalization across the years, so we've set the CapEx guide prudently. Clearly, this year brought a tailwind on the inventory side, roughly $85 million of inventory reduction in fiscal 2026. I expect a modest build next year. It's in select areas, HEC being one of them. Those two combined get us to the greater than 40%. Over time, as CapEx normalizes, I do expect we'll move closer to that 50% we've guided to previously.
Laurence Alexander
analystGot it, thanks. On pharma durability, I'm just a bit curious what your order books and perhaps customer activity point to for growth, say in 2027, and whether any customer inventory normalization is showing up that might alter that trajectory.
Guillermo Novo
executiveAll in all, the order book is quite healthy. In fact, I'd say October also appears consistent with what we anticipated—nothing unexpected. When you examine inventory accumulation and the patterns historically, typically customers—in a pre-inflationary setting—might stock up somewhat, or when shortages occur, they add some inventory. As Jim noted, we aren't the largest driver of cost. What we supply represents a modest share of total costs; during inflation, this isn't an area where they achieve savings. They likely build in other higher-value parts of their cost structure—that's the current driver. We aren't seeing it, and we don't anticipate that becoming the major factor, since it offers customers very little value. What we observed was really during 2022, when shortages existed. Additives and ingredients come in small volumes, and it's comparable to a restaurant—you can't cook without the spices. You don't want to be depleted of those; that's where inventory accumulation shows up affecting additives and ingredients. That's what we witnessed in '22, followed by destocking in '23. That isn't the pattern at present. We don't anticipate that going forward.
Laurence Alexander
analystThank you.
John Roberts
analystThanks. Edlain Rodriguez here, speaking for John. Morning, everybody. One quick question about Personal Care — this may be directed at Jim. We're noticing a bit of softness in oral care as well as household care. Is there anything particular happening in those markets, or is it really, as you put it, simply a matter of timing? And does that imply we ought to look for improved comps in the next quarter, after that timing issue gets sorted out?
Jim Minnicucci
executiveThanks for asking. As I mentioned during my prepared remarks, this really was confined to a single region. Specifically, it came down to order timing in North America. When you look at oral care and home care in the other regions, all of them were up year over year in those areas. Even looking at places such as China on a full-year basis, we've witnessed tremendous growth in oral care alongside local oral care companies there. Over the course of this year, we launched a new thickening polymer for toothpaste, and it's seeing great market adoption. All in all, oral care had a really good year, and we expect that to carry on in 2027.
John Roberts
analystThanks. Here's another one about raw materials, perhaps for Guillermo or William. Could you discuss the increases in raw material costs that you've been seeing, along with your capacity to lift prices in order to offset them? How have those conversations with your customers gone? And also, is passing through those costs easier for some of the businesses and harder for others?
Guillermo Novo
executiveOkay, so once more, I’ll start with a broad-level question, and William can fill in some of the specifics regarding the inflationary piece. Broadly speaking, one, we’re additives — we aren’t the main cost driver for customers. Two, we’re not petrochemical; our exposure on that side is far smaller. Don’t expect us to raise prices the way businesses tied to propylene, ethylene, and all those types of chains would. Ours is far more restrained, at two 1% to 3% growth, depending on the business. We don’t merely offset inflation — we can also protect the margin for what we do. We don’t grow and drive performance through pricing because of inflationary designs. We value-price. This is more about protection. You launch, we position the product well, and then volume growth is what will drive our performance. This is no different. We tended to try to move in, act quickly, and get out of the way for customers. They’ve got bigger problems and bigger challenges with other costs and other raw materials. We want to make sure they understand that we’re not taking advantage of the situations, we don’t do anything of that nature; it’s been pretty smooth. Over the last few years, you’ve seen that we’ve been able to do this pretty well, and I think the team did a fantastic job moving quickly to do what we needed to do and just that with our customers. William, do you want to...
William Whitaker
executiveYes. Hi, Edlain, and good morning. Regarding pricing, I hope it's evident that if you look back a few earnings calls, when inflation truly began accelerating in this area, we made a commitment to offset it and provided some guidance regarding how that might affect us. In the end, we delivered on that. Pricing declined 2 points during Q2 and rose 2 points in Q4 — that's a 400-basis-point swing across the recent two quarters — and the team has performed very well throughout every business unit. As for which units, all of them are feeling it, though the biggest effects so far have come from Specialty Additives and Intermediates, and obviously our pricing figures show we've been able to go out and secure that. Looking toward next year, how does it shape up? Many of the steps we took reflected costs from earlier this year, so although conditions have been volatile, we really haven't seen them widen out far beyond where they stood at that time. Right now, we're assuming we can repeat what we accomplished this year, and with any further changes, we'll go out and offset them across the business units. Carryover pricing ought to provide a modest tailwind during the first half, but you also have raw material carryover depending on where the raw material basket sits today. On the whole, we feel confident in our capacity to handle pricing amid a volatile environment.
John Roberts
analystPerfect. Thank you very much.
Steven Haynes
analystMorning, everyone — thanks for having me, and thanks for the question. I'd like to ask about the EBITDA guidance. I know you haven't offered any quarterly specifics, but could you help us get a sense of how the year shapes up — perhaps at the midpoint, how the first half compares with the second half, and whether there's anything unusual worth flagging there?
Guillermo Novo
executiveFrom an outside view, there's nothing really out of the ordinary. On the timing side—William, you may want to address this—it's just a matter of timing, such as when turnarounds happen and so on, but that comes down more to timing. William, would you like to add anything?
William Whitaker
executiveYes, that's right. Hello, Stephen. Good morning. Broadly speaking, when it comes to how the year takes shape and the various elements at play, I don’t expect it to look vastly different from what we’ve seen historically. Typically, our second half generates between 55% and 60% of full-year EBITDA. Looking at '27, I would say the second-half weighting ought to be somewhat less pronounced than what we saw this year, and obviously that comes down to one factor: the Calvert City situation and the weather effects we dealt with during the first half of last year. That represented a $20 million figure, which was fairly substantial. I do anticipate a solid margin improvement across Life Sciences, Personal Care, and Intermediates during the first half. As far as seasonality goes, there’s nothing out of the ordinary, just as Guillermo mentioned. The first quarter is typically our slowest period, and I expect that pattern to hold. As the team mentioned, we're seeing momentum in volume mix across a few areas—Globalize and Innovate—plus we're lapping some of the effects in our secondary markets, namely construction and energy. Pricing carryover will be strongest during the first half of next year. Then there's the point Guillermo raised, which is normal for us: we usually schedule turnarounds at the cellulosics assets during the December quarter, which marks the seasonal low for the coating season, and we're doing so this year. Finally, I'd add the Hopewell piece. Since this is the seasonal low point, it gives us a chance to go out and build inventory in that area. So we do expect throughput at Hopewell to rise as the year goes on, though there is a negative carryover effect in Q1 stemming from how it ran in the second half of this year. I hope that answers it, but those are really some of the moving pieces as we think about how next year shapes up.
Steven Haynes
analystYep, no, appreciate the color. Thank you.
Josh Spector
analystHello, and good morning. I'm sorry if this was already covered, but I wanted to ask about the CapEx step-up. It caught us off guard, at least, because we assumed much of the innovation-led growth would come from repurposing with lower capital intensity. What's behind the step-up at this point?
Guillermo Novo
executiveJosh, we fielded that question a little earlier, and the thing is, it's really about timing. As part of the network optimization with HEC, our current focus is simply on stabilizing and normalizing productivity at Hopewell, and we've put investments in there. Over the longer term, we do need some debottlenecking. The original plan was to handle it in the outer years, more like 2029, '30. We made the decision to pull that forward. What I was really getting at in my comment is that there's substantial pent-up demand, particularly in coatings, in the coatings space. This year, we expected some recovery in North America and Europe, and that didn't materialize. There's a great deal of pent-up demand: the real estate market, construction around the world, especially here in the U.S. There's a probability — and it's not insignificant — that we could begin to see a pick-up in demand after a very muted market, both in new construction, in real estate, and I'd say the DIY market. We don't want to take any risk, so we're simply saying, "Look, let's move it up" — it's only a year, year and a half forward — have the capacity ready, and we'll proceed so that we have more normalcy in our production planning, and we're not rushing at the last minute to add capacity.
William Whitaker
executiveJosh, on that other piece, I’d just add by way of reinforcement that we set the guidance prudently — right, we’re being deliberate about the up to $140 million. We’ve built in some cushion around the project timing; we’ll bring you an update as the year goes on, but my expectation is that this too will normalize once we’re through it.
Guillermo Novo
executiveTypically, we likely wouldn't have the ability to deploy that amount of money within a single year, so it would carry into the following year; that figure represents roughly a ceiling if you simply assume the entire project's spend lands in 1 year at 100%.
Josh Spector
analystAll right. That seems reasonable to me. I’ll circle back on it afterward. It simply struck me as strange timing to accelerate a coatings recovery, since nobody appears especially enthusiastic about that right now. Let me switch topics and ask about innovation-led growth, that $45 million. How would you divide it between incremental products and the more new-to-the-world kinds of products you’ve launched? What does that split look like, and does it affect your confidence level in any way?
Guillermo Novo
executiveYes. Josh, a couple of points. First, returning to what you said about HEC and our work there: keep in mind that our plants are operating quite well overall when it comes to capacity utilization rates. We encountered a problem in a single product line at one plant, yet everything else is in good shape. We want to ensure we’re well positioned on the supply side, since if any pickup occurs, we want to be prepared for it throughout our network. We currently have three plants rather than four, so that factors into the reasoning; regarding innovation, near term, core innovation remains the larger contributor, given the timing of things and how the portfolio is structured. If you consider Life Science, it’s a pipeline, correct? New items will require more time to arrive. Likewise, in the other businesses, we’re launching some of these newer products, but many of the wins we’re achieving involve things we’ve worked on over the last 2 years—in Globalize especially, which is a major driver—and also, if you look at coatings, much of their growth comes from new rheology modifiers on the synthetic side, new multifunctional HECs and multifunctionality in the additive base, new additives. Those all sit more in the core area; then clearly, the emphasis with the new technologies is on launches and commercialization. The ramp rates will arrive over time as these new technologies truly begin to take hold. They’ll feature more in the outer years, though not so much in the '27.
Josh Spector
analystThanks.
David Begleiter
analystMorning — Emily Fusco here, sitting in for Dave. I was hoping you might be able to give us a bit of color around the possible sale process, given some of what's come out in the news lately, or let us know whether anything new has developed on that front that you can talk about. Thanks.
Guillermo Novo
executiveThere isn't a great deal we're able to say. Our habit, as always, is to stay silent on rumors, speculation, and all the chatter that's floating around. I believe, as we've mentioned before, our attention is on what's within our control — carrying out our strategy. Whichever scenario you pick, performance is the largest driver of value creation; that's genuinely where the team has been directed to concentrate. It comes down to executing, getting productivity moving, and that has been our difficulty in 2026, rather than the outside environment. It's that piece, and once we sort it out, we'll be sitting in a very strong spot in 2027, pushing Globalize and Innovate forward, and simply executing across our portfolio. That is the main priority for everyone right now.
David Begleiter
analystUnderstood. Thanks. So perhaps just to shift gears—apologies if I overlooked this—but could you, or are you able to, put a number on the EBITDA effects coming from Hopewell in 2026 or Q4, and perhaps how much year-over-year gain, if any, is baked into the 2027 guidance?
William Whitaker
executiveCertainly. Hi, Emily, this is William. Regarding the full-year impact on an operating basis, I'll begin there and afterward convert it into the financial effect. On operating performance, we came in underabsorbed relative to our original plan this year by roughly $17.5 million. Not all of that resides in Specialty Additives, though the large majority does. The important thing to remember is that part of it carries into the following year—approximately $5 of that $17 will hit us in Q1, given how the site operated during the second half. Then what matters greatly, I think, is the operational ramp going forward—what we accomplish from this point on in terms of generating throughput and productivity at the site to back existing sales and existing demand. Looking ahead to '26, '27, '28, along that trajectory, we anticipate raising output at Hopewell by roughly 25%, and then by a similar additional order of magnitude the year after. The plans are set, and that's truly a crucial element for us. Then when you look at fiscal '27, you've got the $5 million carryover. We do expect to more than offset it over the remainder of the year, and it should be an incremental positive for fiscal '27. Then the real place where you gain the EBITDA leverage is as you move into fiscal '28, producing at that higher output level on the fixed cost base. Hope that's helpful.
Guillermo Novo
executiveEmily, the remaining piece is that the overall effect was substantial, since it amounted to an additional $20 million — if you break out the outage, the freeze, and the equipment failure at Calvert, that came to roughly $15, and weather contributed another $5. Those two items are now lapped, and as William mentioned in his remarks, production has returned to normal. That particular issue is already behind us. As for the year-on-year comparison, this year all the external factors and all the execution of strategy went according to plan. The shortfall came on the operating side. My sense is that we have already lapped 60% of it, and at this point the real focus is on the Hopewell side, on one technology where we need to raise productivity.
David Begleiter
analystGreat, thanks.
Mike Harrison
analystMorning, hello. On Specialty Additives, you said deliberate actions were taken to reduce exposure to sales with lower margins, particularly in construction. Can you tell us a little more about what exactly you're doing in that area, and how revenue and timing could shape up as you pull out of some of that lower-margin business?
Guillermo Novo
executiveAppreciate the question. We're keen to make this clear. As our comments noted, the two areas where smaller businesses sit inside the portfolio are energy and resources and construction, but the shift has been meaningful. On energy and resources, I'd frame it around the Iran war—it's genuinely thrown a lot of demand off there. Again, probably a small-business impact, but overall the net effect is likely around $30 million. The business is now pretty much at the bottom, we expect, and as we move forward, that'll be recovery. Construction is different. We were at $120 million-plus when we were running the business for absorption and just trying to load the plant. That is now much smaller in terms of our overall portfolio. What this is about is that we hold some truly solid operations in the construction space, particularly at the upper end, and we remain dedicated to serving those clients. Our aim is to keep both demand and supply in balance, yet a certain margin still exists that we draw on to load the MC unit we operate. Pharma comes first. We'll treat this as supplemental volume, correct? For us, construction will never expand in any meaningful manner. When we say the construction market isn't expanding, that isn't what drives us. It'll be a fairly stable operation overall, fluctuating based on how much we need to keep the plant loaded, and we'll aim to retain the premium construction segments we favor and have promised to our customers.
William Whitaker
executiveGuillermo, and Mike, I’d also add another way to look at this: this isn’t a new dynamic. It became clear in Q4 and Q3 because the team has done such a good job in performance specialties and coatings, so you clearly do get some offset on the construction side. One important point, I think, is that it isn’t new, so in Q1 we are going to lap that impact in terms of some of these choices. Because you asked how much of it has already happened: going into Q1 of fiscal ’27, I would expect the construction business to be relatively stable year-on-year, just to be clear on that.
Mike Harrison
analystOkay, thank you. That's quite useful. My second question concerns the Personal Care margin going forward. It looks as though we might be getting some gains from volume leverage, from optimizing plants, and perhaps the mix is improving too, but I'm just curious how far margin can climb from roughly this 30% EBITDA margin level when we look ahead to the next year or two. Thanks.
Guillermo Novo
executiveI'll hand that one to Jim. As you noted, mix matters a great deal. A lot of strong products are emerging from our biofunctionals, our microbial protection, and even the fresh projects they're bringing to market — all of those carry above-average margins, and mix plays a major role in the story ahead as we execute our strategy. Jim, would you like to add anything else?
Jim Minnicucci
analystThanks, Guillermo. Hey, Mike, appreciate the question. Like you mentioned, yes, we're quite pleased to have 30% margins this quarter. As we've discussed over the last couple of years, that's genuinely something we've been striving toward—reaching that high 20, 30% margin range—and we still see more upside and further headroom ahead from here. Obviously, during the first half of 2027, we ought to see some margin improvement and benefit compared with the prior year, since the one-time items won't repeat—specifically the Calvert City event and last year's weather event; then moving forward, as we've said, our commercial engine is truly gaining traction, we're seeing very strong growth, and our high-margin businesses, biofunctional actives and microbial protection, are growing at double digit, which we expect to keep up in 2027 and beyond. Favorable mix from volume growth will give us added margin uplift. Right now we're focused on reaching that mid-30% range.
Mike Harrison
analystThank you.
John McNulty
analystHi, Margarita Margulis here, filling in for John. Thanks for taking my question. Could you give us a bit more detail on the new energy storage customer wins, including how large the opportunity is and perhaps when you expect those volumes to ramp up?
Guillermo Novo
executiveI'll address that. We don't discuss specific customer contracts and such, but it's a large, long-term contract—a U.S. big battery, EV and energy storage. It's multi-year with a significant volume. It'll bring a lot of loading stability to our Intermediates business and our integrated footprint. The first year is the one we'll be watching. We have our figures from what they've provided; the first year tends to be the noisiest because of ramp rates alone, and that's this year. Everything is in motion. It's now about supporting the customer and what they'll be ramping over the next 6, 12 months.
John McNulty
analystUnderstood, thanks. Turning to capital allocation — with leverage sitting a bit above 2 times, have you shifted your appetite for M&A as we head into fiscal '27? And separately, has anything changed regarding the Capital Allocation Advisory Committee — any updates on that front?
Guillermo Novo
executiveNo, nothing's changed. Our strategy is clear. I hope everyone can see that everything taking place aligns with that strategy and with what we're doing. We're very clear about what we want when it comes to bolt-ons, with pharma and personal care as a priority, and about assets that support perhaps the growth of some new technologies or geographic growth around the world. Those are the biggest areas. Regarding your question about the capital allocation committee — they're highly involved and attentive, and above all it's genuinely central to our growth strategy: grasping where we are on execution, how we deploy capital for productivity efforts, getting every plant performing, and over time advancing along their productivity curves, adding value to the business and keeping us competitive. As for Globalize, it isn't solely about capital — it's resources, every investment we're making to carry out our strategy, which is performing very well, and we intend to sustain that momentum. They're examining and getting a handle on our innovation portfolio—taking a close look at our technologies and grasping them—but even more crucially, they're identifying which of those are more scalable, what capital is required in those areas, and how we can keep the momentum going, while of course getting a handle on our bolt-on type activities. As is usual, over the long term, we've been developing our larger strategy on scale for Ashland—things we intended to accomplish across the last two years. The committee is working intensively on all of those matters, just as they've always done. Pretty robust, and it all centers on executing our strategy and growth.
William Whitaker
executiveOne more thing I would mention is that our approach to capital allocation this year was highly deliberate, aimed at reinforcing the balance sheet. In part, that means ensuring we possess the complete range of alternatives as we head toward the debt maturity coming up. We have a January '28 bond tower, €500 million. We feel very good about our cash position at $480 million plus $500 on the revolver. That affords us considerable flexibility as we consider that situation. Credit spreads remain quite appealing, though base rates have clearly shifted across many jurisdictions. We appreciate the flexibility that comes from accumulating cash on the balance sheet ahead of it, and there is more to come as we determine how we will handle the bond tower.
John McNulty
analystThanks.
Guillermo Novo
executiveWonderful, thanks. Appreciate everyone's questions and for joining us. I hope the excitement we feel comes through to you. As I see it, 2026 has actually unfolded quite nicely where our overall strategy and commercial execution are concerned. Clearly, we did have gaps on the operating side. Those are one-time issues. 60% of them are already behind us. We're working on the remaining ones. These are one-time things; we made a lot of changes. What excites us is this: look, our transformation is complete. The last few years have involved a lot of work, a lot of moving parts and change. It's done. We have reorganized the company and altered our cost structure. Our portfolio focus has shifted considerably, moving more toward additives, ingredients, and consumer. We have streamlined the manufacturing network. We have singled out four businesses to pursue globalization and market share gains, and we have completely rebuilt our innovation portfolio: a better set of tools and fresh opportunities that generate incremental growth for us. Those actions are complete. Execution is where our team is concentrated. From a commercial standpoint, if you examine the 2026 results, they line up very closely with what we told you: markets that are resilient, growth of higher quality, and every one of the drivers. That is the reason 2027 has us excited. What matters at this point is resolving what needs addressing in a single product line at a single plant from a productivity standpoint, and after that, concentrating on execution. Our strategy is sound, our teams are quite far along, and none of this is new for us. We completed our transformation while others across the industry are only now beginning theirs, which lets us keep our attention fixed and carry out our strategy regardless of conditions in the external market. There are many growth drivers specific to our company that can genuinely propel our performance going forward, and that ranks as our top priority. I’m eager to speak with all of you in the weeks ahead, and I’m grateful for your backing—thanks very much.
Operator
operatorThanks. Appreciate everyone joining today's conference call once more. That brings the program to a close, so you're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Ashland Inc. transcript — plus 133,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Ashland Inc. earnings transcripts and 133,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Ashland Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.